Antengene to Present at the 39th Annual J.P. Morgan Healthcare Conference
SHANGHAI and SAN FRANCISCO, Jan. 11, 2021 /PRNewswire/ Antengene Corporation Limited ( Antengene , SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncology, today announced that it will participate in the 39
th Annual J.P. Morgan Healthcare Conference, which is the largest healthcare investment symposium in the industry. Dr. Jay Mei, Founder, Chairman and CEO of Antengene, will present a corporate overview on Monday, January 11, 2021 at 8:40 a.m. EST (Monday, January 11, 2021 at 9:40 p.m. BJT).
Date:Monday, January 11
Idorsia Pharmaceuticals Ltd: Idorsia to debut at the 39th J.P. Morgan Healthcare Conference - Major catalysts expected in the near-term - Daridorexant NDA submitted to the US FDA
Allschwil, Switzerland - January 11, 2021
Idorsia Ltd (SIX: IDIA) today announced that Jean-Paul Clozel, Chief Executive Officer of Idorsia, will present at the 39
th J. P. Morgan Healthcare Conference on January 12, 2021 at 09:10 Eastern Time / 15:10 Central European Time. The conference will take place fully virtual.
Jean-Paul will roll-out Idorsia s long-term vision and describe the progress made so far in delivering on the company priorities. He will also present why 2021 will be a key year for Idorsia with major catalysts expected in the near-term. Follow this
OBI Pharma, Inc. to Present at the 39th J.P. Morgan Healthcare Conference
TAIPEI, Taiwan, Jan. 6, 2021 /PRNewswire/ OBI Pharma, Inc., a Taiwan biopharma company (TPEx: 4174), announced that Tillman Pearce, MD., Chief Medical Officer, will present a company and clinical development overview at the 39
th Annual J.P. Morgan Digital Healthcare Conference on Monday, January 11, 2021 at 11:00 a.m. EST/ 8:00 a.m. PST.
The presentation slides will be available online at www.obipharma.com on January 12, 2021.
About OBI Pharma
OBI Pharma, Inc., is a Taiwan biopharmaceutical company that was established in 2002. Its mission is to develop and license novel therapeutic agents for unmet medical needs against cancer targets such as Globo Series (including Globo H, SSEA-3 and SSEA-4), AKR1C3, and other promising targets.